MORE than 200 jobs are to go at a healthcare manufacturing plant thanks to an “adjustment” in operations to put a focus on new medical devices.
Staff at Abbott in Clonmel were told that the company is seeking about 200 redundancies in its vascular manufacturing facility on the edge of the town, while “a few dozen” contractor positions won’t be renewed when contracts expire at the end of March.
Abbott currently employs more than 1,400 people at its Clonmel site and the redundancies will follow a 30-day “consultation period” with employees.
In a statement, the company said it hopes to achieve the redundancies on a voluntary basis.
“The proposed redundancies are part of adjustments we are making to meet the evolving needs of the business and to remain competitive in a challenging global environment,” it said. “The facility remains strategically important to Abbott’s global vascular manufacturing network.”
The Clonmel site is to focus primarily on the manufacture of newer, advanced medication devices “going forward,” according to the company.
This will incorporate a drug and device combination such as Absorb, which has been developed by Abbott for the treatment of coronary artery disease.
“Capital investment will be made at the site this year to enable it to manufacture these innovative medical technologies,” the company said in its statement.
“We regret the impact of this adjustment on our employees in Clonmel and the wider community, and our focus is on supporting our impacted employees. Favourable redundancy terms and outplacement services will be provided to affected employees.”
At the moment, Abbott’s Clonmel plant manufactures a range of devices for global markets which are used in the treatment of vessel diseases of the heart and peripheral blood vessels.
Clonmel is the only one of Abbott’s 11 locations across Ireland which will be affected by yesterday’s announcement. The company employs more than 3,200 people in this country.